Reuter VE - Search Results

1

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.

Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I, Balar AV, Kim PH, Lin O, Weinhold N, Sander C, Zabor EC, Janakiraman M, Garcia-Grossman IR, Heguy A, Viale A, Bochner BH, Reuter VE, Bajorin DF, Milowsky MI, Taylor BS, Solit DB. Iyer G, et al. Among authors: reuter ve. J Clin Oncol. 2013 Sep 1;31(25):3133-40. doi: 10.1200/JCO.2012.46.5740. Epub 2013 Jul 29. J Clin Oncol. 2013. PMID: 23897969 Free PMC article.

2

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

3

Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies.

Motzer RJ, Rodriguez E, Reuter VE, Samaniego F, Dmitrovsky E, Bajorin DF, Pfister DG, Parsa NZ, Chaganti RS, Bosl GJ. Motzer RJ, et al. Among authors: reuter ve. J Natl Cancer Inst. 1991 Mar 6;83(5):341-6. doi: 10.1093/jnci/83.5.341. J Natl Cancer Inst. 1991. PMID: 1847433

4

Pathology of bladder cancer: assessment of prognostic variables and response to therapy.

Reuter VE. Reuter VE. Semin Oncol. 1990 Oct;17(5):524-32. Semin Oncol. 1990. PMID: 2218564 Review. No abstract available.

5

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.

Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, Schultz PK, Cordon-Cardo C, Scher HI. Sarkis AS, et al. Among authors: reuter ve. J Clin Oncol. 1995 Jun;13(6):1384-90. doi: 10.1200/JCO.1995.13.6.1384. J Clin Oncol. 1995. PMID: 7751883

6

Tumor suppressor gene alterations in bladder carcinoma. Translational correlates to clinical practice.

Dalbagni G, Cordon-Cardo C, Reuter V, Fair WR. Dalbagni G, et al. Surg Oncol Clin N Am. 1995 Apr;4(2):231-40. Surg Oncol Clin N Am. 1995. PMID: 7796283 Review.

7

Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.

Motzer RJ, Rodriguez E, Reuter VE, Bosl GJ, Mazumdar M, Chaganti RS. Motzer RJ, et al. Among authors: reuter ve. J Clin Oncol. 1995 Jan;13(1):274-82. doi: 10.1200/JCO.1995.13.1.274. J Clin Oncol. 1995. PMID: 7799031

8

Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer.

Dalbagni G, Presti JC Jr, Reuter VE, Zhang ZF, Sarkis AS, Fair WR, Cordon-Cardo C. Dalbagni G, et al. Among authors: reuter ve. Diagn Mol Pathol. 1993 Mar;2(1):4-13. Diagn Mol Pathol. 1993. PMID: 7904525

9

Genetic alterations associated with bladder cancer.

Cordon-Cardo C, Dalbagni G, Sarkis AS, Reuter VE. Cordon-Cardo C, et al. Among authors: reuter ve. Important Adv Oncol. 1994:71-83. Important Adv Oncol. 1994. PMID: 7911446 Review. No abstract available.

10

Altered patterns of MDM2 and TP53 expression in human bladder cancer.

Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C. Lianes P, et al. Among authors: reuter ve. J Natl Cancer Inst. 1994 Sep 7;86(17):1325-30. doi: 10.1093/jnci/86.17.1325. J Natl Cancer Inst. 1994. PMID: 8064890

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

637 results

Search Page